Literature DB >> 2459971

Inactivation of human lipase by proteases.

R Thiruvengadam1, E P DiMagno.   

Abstract

To determine if human lipase is inactivated by trypsin and chymotrypsin, we intubated 22 human subjects with an oroduodenal tube and stimulated pancreatic secretion with cholecystokinin octapeptide. The duodenal aspirate from each subject was divided into a control and a test sample and incubated in a 37 degrees C water bath for 2 h. An inhibitor of trypsin or chymotrypsin or more of one of these enzymes was added to the test sample. We found that the loss of lipase activity was partly prevented by inhibiting trypsin with aprotinin (910 KU/ml; P = 0.03) and was accelerated by adding bovine trypsin (2.5 mg/ml; P = 0.01). Inhibiting chymotrypsin with turkey egg white (2.5 mg/ml) totally abolished the loss of lipase activity (P = 0.01), and addition of bovine chymotrypsin (5 mg/ml) accelerated the loss of lipase activity more than adding trypsin (P = 0.01). After inhibiting chymotrypsin (to maintain lipase activity), increasing trypsin activity by adding a single or repeated doses of trypsin did not decrease lipase activity. Conversely, the addition of a single dose of chymotrypsin after inhibiting trypsin activity markedly decreased lipase activity (P less than 0.004). In conclusion, chymotrypsin is a more potent inactivator of human lipase than trypsin; chymotrypsin inactivates lipase in the absence of trypsin, but trypsin inactivation of lipase requires chymotrypsin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459971     DOI: 10.1152/ajpgi.1988.255.4.G476

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Pancreatic enzyme replacement therapy.

Authors:  P Layer; J Keller; P G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 2.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 3.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

4.  No negative feedback regulation between plasma CCK levels and luminal tryptic activities in patients with pancreatic insufficiency.

Authors:  T Nakamura; K Takebe; K Kudoh; M Ishii; K Imamura; H Kikuchi; F Kasai; Y Tandoh; N Yamada; Y Arai
Journal:  Int J Pancreatol       Date:  1995-02

5.  Effect of cholecystokinin octapeptide and atropine on human colonic motility, tone, and transit.

Authors:  M D O'Brien; M Camilleri; G M Thomforde; J A Wiste; R B Hanson; A R Zinsmeister
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

6.  Pancreatic exocrine insufficiency after pancreaticoduodenectomy is more prevalent with pancreaticogastrostomy than with pancreaticojejunostomy. A retrospective multicentre observational cohort study.

Authors:  Geert Roeyen; Miet Jansen; Laure Ruyssinck; Thiery Chapelle; Aude Vanlander; Bart Bracke; Vera Hartman; Dirk Ysebaert; Frederik Berrevoet
Journal:  HPB (Oxford)       Date:  2016-10-07       Impact factor: 3.647

Review 7.  Pancreatic enzymes in chronic pancreatitis.

Authors:  P Layer; G Holtmann
Journal:  Int J Pancreatol       Date:  1994-02

8.  Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy.

Authors:  M J Bruno; E A Rauws; F J Hoek; G N Tytgat
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

Review 9.  Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation.

Authors:  Raffaele Pezzilli
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

Review 10.  Treatment of pancreatic exocrine deficiency.

Authors:  Martin Sarner
Journal:  World J Surg       Date:  2003-10-13       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.